14-Aug-2026
Top Executive Makes Notable Move With Alpha Tau Medical Stock
TipRanks (Wed, 12-Aug 10:15 PM ET)
Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 10-Aug 4:01 PM ET)
Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Globe Newswire (Mon, 10-Aug 8:00 AM ET)
Alpha DaRT Combo Achieves 100% Response Rate and Extends Survival in Head and Neck Cancer Trial
Market Chameleon (Tue, 21-Jul 4:57 AM ET)
Globe Newswire (Tue, 21-Jul 8:30 AM ET)
Globe Newswire (Wed, 15-Jul 8:30 AM ET)
PRNewswire (Thu, 25-Jun 11:35 AM ET)
Globe Newswire (Tue, 23-Jun 8:30 AM ET)
Market Chameleon (Fri, 12-Jun 6:46 AM ET)
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Alpha Tau Medical Ltd. - trades on the NASDAQ stock market under the symbol DRTS.
As of August 14, 2026, DRTS stock price declined to $14.25 with 304,557 million shares trading.
DRTS has a beta of 1.93, meaning it tends to be more sensitive to market movements. DRTS has a correlation of 0.13 to the broad based SPY ETF.
DRTS has a market cap of $1.32 billion. This is considered a Small Cap stock.
Last quarter Alpha Tau Medical Ltd. - reported $0 in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-230,136 and missed earnings estimates by -$.36.
In the last 3 years, DRTS traded as high as $14.75 and as low as $1.75.
The top ETF exchange traded funds that DRTS belongs to (by Net Assets): IZRL, EHLS, AVSD.
DRTS has outperformed the market in the last year with a price return of +345.3% while the SPY ETF gained +21.5%. DRTS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +36.9% and +20.9%, respectively, while the SPY returned +4.0% and +3.9%, respectively.
DRTS support price is $13.83 and resistance is $15.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRTS shares will trade within this expected range on the day.